Mjt & Associates Financial Advisory Group, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Mjt & Associates Financial Advisory Group, Inc.
- $104 Billion
- Q1 2025
A detailed history of Mjt & Associates Financial Advisory Group, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mjt & Associates Financial Advisory Group, Inc. holds 54 shares of SUPN stock, worth $1,749. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54Holding current value
$1,749% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
300Shares Held
59.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$337 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$199 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$157 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$93.2 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$85.2 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.73B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...